In recent years, there has been an increased interest in the clinical use of brain markers. The
S100B is a calciumbinding peptide and is used as a parameter of glial activation and/or …

Antipsychotic medications (APs), particularly second-generation APs, are associated with
significant weight gain in schizophrenia patients. Recent evidence suggests that the immune …

There is growing evidence that immune/inflammatory processes are related to the etiology of
schizophrenia. Danger-/damage-associated molecular patterns (DAMPs), also called …

S100B is a calcium-binding protein secreted in central nervous system from astrocytes and
other glia cells. High blood S100B levels have been linked to brain damage and psychiatric …

The research for peripheral biological markers of schizophrenia, although abundant, has
been unfruitful. In the last 2 decades, the S100B protein has made its own room in this area …

This chapter has carried out a review of the literature and combined this with the results of in-
house studies to identify candidate blood-based biomarkers for schizophrenia and …

Astrocytes regulate multiple processes in the brain ranging from trophic support of
developing neurons to modulation of synaptic neurotransmission and neuroinflammation in …

Glial damage and immune dysfunction are involved in pathogenesis of schizophrenia.
However, interaction between glial damage and immune dysfunction in schizophrenia is …

S100B is a calcium-binding protein, which is produced primarily by glial cells. It modulates
the proliferation and differentiation of neurons and glia by affecting protective and apoptotic …

Mesial temporal lobe epilepsy (MTLE) is a common type of intractable epilepsy
characterized by astroglial gliosis. The S100B was viewed as an astrocyte marker and …